Is Longeveron, Inc. overvalued or undervalued?

As of 14 August 2024, Longeveron, Inc. has moved from a grade of "does not qualify" to "risky," indicating a significant downgrade in its valuation outlook. The company is currently assessed as overvalued given its financial metrics, particularly its P/E ratio which is not applicable due to losses, and a Price to Book Value of 1.08. Additionally, the EV to EBITDA stands at -0.29, highlighting negative earnings before interest, taxes, depreciation, and amortization, which is concerning for potential investors.
In comparison to its peers, Longeveron shows a stark contrast with Microbot Medical, Inc., which has a P/E of -7.54, and Surrozen, Inc., which has a P/E of 6.49. The company's ROCE is alarmingly low at -508.69%, and its ROE is also negative at -98.64%. Given these ratios and the overall performance, including a year-to-date stock return of -33.53% compared to a 2.44% return from the S&P 500, it reinforces the notion that Longeveron is overvalued in its current state.